Based on very promising results of the Chrysalis phase 1/2 study for non-small-cell lung cancer (NSCLC) with EGFR Exon20 insertions (Ex20+, NCT02609776), an application for accelerated approval was filed by the FDA and EMA in late 2020, while the drug is already available through an international compassionate use program for these patients [85]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.